Cargando…
Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway
Dysregulated hepatic steatosis may lead to chronic liver inflammation and nonalcoholic steatohepatitis (NASH). Recent studies have suggested that exendin-4, a glucagon-like peptide-1 agonist, may be a promising therapeutic for hepatic steatosis and NASH. However, the molecular mechanisms underlying...
Autores principales: | Yu, Hsin-Hsien, Wang, Hao-Chen, Hsieh, Mao-Chih, Lee, Ming-Che, Su, Bor-Chyuan, Shan, Yan-Shen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307340/ https://www.ncbi.nlm.nih.gov/pubmed/35872844 http://dx.doi.org/10.1155/2022/4246086 |
Ejemplares similares
-
Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway
por: Fang, Yunyun, et al.
Publicado: (2020) -
Benefit of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Bidirectional Chemotherapy for Patients with Gastric Cancer with Peritoneal Carcinomatosis Considering Cytoreductive Surgery
por: Yu, Hsin-Hsien, et al.
Publicado: (2023) -
Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis
por: Hsiao, Pi-Jung, et al.
Publicado: (2017) -
PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation
por: Tong, Lei, et al.
Publicado: (2019) -
Nuciferine protects against high-fat diet-induced hepatic steatosis and insulin resistance via activating TFEB-mediated autophagy–lysosomal pathway
por: Du, Xiliang, et al.
Publicado: (2022)